DYN Dyne Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818794 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.7%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-74.6%
ROA-57.6%
ROIC (approx.)-225.2%
Asset turnover—
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.21x
Current ratio12.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $398.33M | $281.41M | $210.76M | $142.76M | $121.31M |
| SG&A expense | $69.85M | $62.48M | $31.40M | $28.20M | $28.72M |
| Operating income | -$468.18M | -$343.89M | -$242.16M | -$170.96M | -$150.03M |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -$149.29M |
| EBITDA | -$466.13M | -$342.21M | -$240.49M | -$169.28M | -$148.94M |
| EPS (basic) | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 |
| EPS (diluted) | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 |
| Weighted avg. shares (diluted) | — | — | — | — | 50.90M |
| Balance sheet | |||||
| Cash & equivalents | $893.37M | $435.45M | $121.63M | $172.15M | $200.82M |
| Short-term investments | $217.19M | $206.82M | $1.47M | $83.86M | $175.75M |
| Current assets | $1.13B | $659.28M | $129.38M | $265.59M | $382.39M |
| PP&E, net | $24.03M | $5.40M | $4.78M | $5.95M | $4.68M |
| Total assets | $1.19B | $691.23M | $165.08M | $306.32M | $425.66M |
| Current liabilities | $50.62M | $42.26M | $51.09M | $28.09M | $28.72M |
| Long-term debt | $148.92M | $0 | — | — | — |
| Total debt | $148.92M | $0 | — | — | — |
| Total liabilities | $214.83M | $61.40M | $73.79M | $53.96M | $57.47M |
| Shareholders' equity | $972.13M | $629.84M | $91.29M | $252.36M | $368.20M |
| Net debt | -$744.45M | -$435.45M | — | — | — |
| Shares outstanding | 164.95M | 102.32M | 61.47M | 55.64M | 51.57M |
| Cash flow statement | |||||
| Operating cash flow | -$403.21M | -$292.37M | -$188.16M | -$153.65M | -$119.56M |
| Capital expenditure | $1.92M | $2.38M | $729,000 | $3.07M | $3.62M |
| Free cash flow | -$405.13M | -$294.75M | -$188.89M | -$156.71M | -$123.18M |
| Investing cash flow | -$28.75M | -$204.08M | $83.31M | $87.20M | -$137.89M |
| Financing cash flow | $890.31M | $809.89M | $54.32M | $37.39M | $157.82M |
| Depreciation & amortization | $2.05M | $1.67M | $1.67M | $1.68M | $1.09M |
| Stock-based compensation | $45.85M | $45.86M | $19.97M | $15.18M | $17.54M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.